Following history price oscilates between a range of three price pre-sets. I am betting on a trend continuation. Not sure how far down price would move after reaching goal. The bet is 1.5 times the risk.
Write sometning about your psyhology thinking before trade? today is not my day so this will be the only trade I will made. I am concern a little bit about a short squize, but in general trade is quite strate forward
Describe the trade. What you see? there will be trade between support and reistance line
What have I done well for this trade? Enter point was at...
Breaking out from pullback, positioned i lower half of positive trend channel.
Price: Breaking out from pullback, target 16-17
RSI: Breaking out from pullback, having support at 40
MACD: Positive crossover in negative terrain
Tested support at 14 and reacted up. Above SMA200.
This stock has a habit of surprise earnings then up and back down. Highvolitility stock up all year list as institutional holding of 110% (16% float). I believe 14.22 to 14.40 time to jump in. Yesterday around 14.39 in am. Overnight profit taking expect lower open by ~3% wait for up tick and buy. Expect to hold <30days for 6%profit. Thanks RealLifeTrading.com
TYY
Retest gap yesterday. Awesome move today. Hoping FOLD will pull back a little bit more. Morning star reversal on the weekly chart. Above normal bullish volume lately as well. We are also able to get the support/resistance line in between our entry and stop. You could honestly go for a tighter stop, but I'm trying to get some more room to be wrong if needed. We...
1) stockcharts.com - above the green line stocks use an indicator SCTR line (90+). Shows relative strength vs stocks in a similar group. on the current daily chart its 97.9 (real good).
2) using moving averages, you can see the pullback
3) using UCS_MMLO indicator twice on the same chart on TV (100 and 25)...the 100 chart stays green and the 25 shows red. ...
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
FOLD
